Eliquis and Splenic infarction - a phase IV clinical study of FDA data

Summary:

Splenic infarction is reported as a side effect among people who take Eliquis (apixaban), especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months also take Pantoprazole, and have Metastatic malignant melanoma.

The phase IV clinical study analyzes which people have Splenic infarction when taking Eliquis. It is created by eHealthMe based on reports of 189,425 people who have side effects when taking Eliquis from the FDA, and is updated regularly.

What is Eliquis?

Eliquis has active ingredients of apixaban. It is often used in atrial fibrillation/flutter. eHealthMe is studying from 191,861 Eliquis users. Check the latest studies of Eliquis.

What is Splenic infarction?

Splenic infarction (tissue damage of spleen) is found to be associated with 287 drugs and 529 conditions by eHealthMe. Check the latest studies of Splenic infarction.

On Aug, 09, 2026

189,425 people reported to have side effects when taking Eliquis.
Among them, 39 people (0.02%) have Splenic infarction.

Among these 39 people:

How long have people been on Eliquis when they have Splenic infarction? *

What is the gender of people who have Splenic infarction when taking Eliquis? *

female: 28.57 %
male: 71.43 %

What is the age of people who have Splenic infarction when taking Eliquis? *

What are other drugs people take besides Eliquis? *

What are other side effects people have besides Splenic infarction? *

Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 11 people, 28.21%
Dry Skin: 11 people, 28.21%
Hemiparesis (weakness on one side of the body): 8 people, 20.51%
Diarrhea: 8 people, 20.51%
Speech Impairment (Adult) (inability to speak (adult)): 8 people, 20.51%
Weakness: 7 people, 17.95%
Paraproteinaemia (normal or abnormal plasma protein appearing in large quantities): 7 people, 17.95%
Neoplasm Progression (growth of tumour): 7 people, 17.95%
Muscle Aches (muscle pain): 7 people, 17.95%
Pneumonia Aspiration (bronchopneumonia that develops due to the entrance of foreign materials into the bronchial tree): 7 people, 17.95%

What are the existing conditions these people have? *

Malignant Melanoma (skin cancer rises from melancytes): 7 people, 17.95%
Metastatic Malignant Melanoma (spreadable cancer tumour of melanine): 7 people, 17.95%
Stroke (sudden death of a portion of the brain cells due to a lack of oxygen): 6 people, 15.38%
Memory Loss: 5 people, 12.82%
Cerebral Artery Occlusion (blockage of blood vessel of brain by fat or clot): 5 people, 12.82%
Dementia (madness): 5 people, 12.82%
Primary Myelofibrosis (primary disorder of the bone marrow): 5 people, 12.82%
High Blood Pressure: 3 people, 7.69%
Multiple Myeloma (cancer of the plasma cells): 2 people, 5.13%
Uterine Leiomyoma (uterine benign tumour derived from smooth muscle): 2 people, 5.13%

* Approximation only. Some reports may have incomplete information.

Do you take Eliquis and have Splenic infarction?

- Check whether Splenic infarction is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Eliquis:

Eliquis (191,861 reports)

Browse all side effects of Eliquis:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Splenic infarction:

Splenic infarction (287 drugs)

Browse all the conditions that are associated with Splenic infarction:

Splenic infarction (529 conditions)

Related publications that referenced our studies

Misgar, R. A., Bhat, J. A., Wani, A. I., & Bashir, M. I., "Sitagliptin induced splenic infarcts", Clinical Diabetology, 2014 Jan .
Misgar, R. A., Bhat, J. A., Wani, A. I., & Bashir, M. I., "Sitagliptin induced splenic infarcts", Clinical Diabetology, 2014 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on apixaban (the active ingredients of Eliquis) and Eliquis (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.